Alphatec (NASDAQ:ATEC) Issues Earnings Results

Alphatec (NASDAQ:ATEC - Get Free Report) issued its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.23), Zacks reports. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. During the same period in the previous year, the firm posted ($0.34) EPS. The firm's revenue was up 22.2% compared to the same quarter last year. Alphatec updated its FY 2025 guidance to EPS.

Alphatec Stock Up 2.5 %

ATEC traded up $0.31 during midday trading on Thursday, hitting $12.76. The company had a trading volume of 1,379,793 shares, compared to its average volume of 2,080,387. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. Alphatec has a 52 week low of $4.88 and a 52 week high of $12.82. The stock's 50 day moving average price is $10.48 and its 200 day moving average price is $10.00. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -9.97 and a beta of 1.06.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. StockNews.com upgraded shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, January 22nd. Piper Sandler reaffirmed an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research report on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $17.89.

Insider Buying and Selling

In other Alphatec news, CEO Patrick Miles sold 12,691 shares of Alphatec stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the transaction, the chief executive officer now owns 5,857,603 shares in the company, valued at approximately $62,324,895.92. The trade was a 0.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Scott Lish sold 23,183 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $12.03, for a total transaction of $278,891.49. Following the completion of the sale, the chief operating officer now directly owns 844,494 shares of the company's stock, valued at $10,159,262.82. The trade was a 2.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 126,945 shares of company stock worth $1,416,352 in the last ninety days. Corporate insiders own 22.80% of the company's stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.